丙酸睾丸酮对乳腺癌细胞株mda-mb-231增殖影响的研究

《丙酸睾丸酮对乳腺癌细胞株mda-mb-231增殖影响的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20122336蚵妗(E钭走5HebeiMedicalUniversity硕士学位论文科学学位丙酸睾丸酮对乳腺癌细胞株MDA-MB-231增殖影响的研究研究生：商翌导师：李云涛教授专业：外科学二级学院：第四医院2015年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师（或指导小组）的指导下，由本人独立完成。本学位论文研究所获得的研究成果，其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文，第一署名为单位河北医科大学，试验材

2、料、原始数据、申报的专利等知识产权均归河北医科大学所有。否则，承担相应法律责任。，：、.•/».•.研究生签名：L导师签章二象学院领导盖章:7s年,3月t{曰河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外’文中不包含其他人已经发表或撰写的研究成果，指导教师对此进行了审定。本论文由本人独立撰写，文责自负。知1研究生签名：导师签章：-十年3月?,曰目录中文摘要······················································

3、········································1英文摘要······························································································5英文缩写····························································································10研究论文丙酸睾丸酮对乳腺癌细胞株MDA-MB-231增殖影响的研究

4、前言····························································································12材料与方法················································································13结果······················································································

5、······18附图····························································································20附表····························································································25讨论·····································································

6、·······················27结论····························································································31参考文献····················································································32综述乳腺癌内分泌治疗耐药机制的研究······························36致谢·········

7、···························································································48个人简历····························································································49中文摘要丙酸睾丸酮对乳腺癌细胞株MDA-MB-231增殖影响的研究摘要目的：近年来，乳腺癌已经成为威胁女性生命与健康的头号“公敌”。虽然经过系统、正规的综合治疗

8、使乳腺癌的生存率大大提高，但仍有一些特殊类型如三阴性乳腺癌生存获益不太显著。我们把ER、PR和HER-2均为阴性的乳腺癌定义为三阴性乳腺癌。由于缺乏有效的靶向药物，治疗[1]三阴性乳腺癌的方法很少，复发率较